NCT03292536: Merestinib on Bone Metastases in Subjects With Breast Cancer

NCT03292536
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Bone
Additional Notes: 
Exclusions: Known symptomatic brain metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT03292536

Comments are closed.

Up ↑